Form 4: Sionna Therapeutics CEO Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


Michael Cloonan, President & CEO and a Director of Sionna Therapeutics, Inc., reported multiple transactions in common stock on September 17, 2026.

Summary

  • Grant/award: acquired 109,025 Common Stock on September 17, 2026; holds 656,368 after (Direct).
  • Grant/award: acquired 109,025 Common Stock on September 17, 2026; holds 765,393 after (Direct).
  • Grant/award: acquired 436,100 Non-Qualified Stock Option (right to buy) on September 17, 2026; holds 436,100 after (Direct).
  • Disposition to the issuer: disposed of 436,100 Non-Qualified Stock Option (right to buy) on September 17, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Michael Cloonan — Director, Officer (President & CEO)

DateTransactionSecuritySharesPriceValueHeld After
2026-09-17Grant/awardCommon Stock109,025——656,368
2026-09-17Grant/awardCommon Stock109,025——765,393
2026-09-17Grant/awardNon-Qualified Stock Option (right to buy)436,100——436,100
2026-09-17Disposition to the issuerNon-Qualified Stock Option (right to buy)436,100——0

Key Dates

DateDescription
2026-09-17Grant/award (109,025 shares)
2026-09-17Grant/award (109,025 shares)
2026-09-17Grant/award (436,100 shares)
2026-09-17Disposition to the issuer (436,100 shares)

Keywords

insider transaction, Form 4, SION, Sionna Therapeutics, Inc., neutral, Michael Cloonan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.